ClinicalTrials.gg
CompletedNCT02780726Updated Oct 30, 2024

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

A Phase 3 interventional study of roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia, sponsored by Astellas Pharma Inc. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
37th of 43
56 · median 154
Started
2016
with 3 others
Phase 3
25 of 43
1 open now
Registered
21st of 43
by date
Lead sponsor
7 of 43
Astellas Pharma Inc

Among the 43 studies testing roxadustat in Anemia, this one is the 37th largest by enrollment, is one of 4 that started in 2016, is one of 25 in phase 3, and was the 21st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and efficacy of ASP1517 in peritoneal dialysis chronic kidney disease patients with anemia.

03

Conditions studied

  • Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Browse trials for

Keywords

  • Peritoneal dialysis
  • Roxadustat
  • Renal anemia
  • ASP1517
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subject must either:

Be of non-:

  • (defined as at least 1 year without any menses) prior to Screening, or
  • documented surgically sterile Or, if of childbearing potential,
  • Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
  • And have a negative pregnancy test at Screening
  • And, if heterosexually active, agree to consistently use two forms of highly effective form of (at least one of which must be a barrier method) starting at Screening and throughout the study period and continued for 28 days after the final study drug administration.

    • Female subject must agree not to breastfeed starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Female subject must not donate ova starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective form of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 12 weeks after the final study drug administration
    • Male subject must not donate sperm starting at Screening and throughout the study period and, for 12 weeks after the final study drug administration
    • Subjects who have not received Erythropoieses Stimulating Agents (ESAs):
  • Subjects who have been receiving peritoneal dialysis for more than 4 weeks before the screening assessment
  • Subjects who have never received ESAs after starting peritoneal dialysis, or subjects who have not received ESAs within 6 weeks before the screening assessment.
  • Mean of the subject's two most recent values before randomization during the Screening Period must be \<10.5 g/dL with an absolute difference ≤1.3 g/dL between the two values
  • Either transferrin saturation (TSAT) ≥ 5% or serum ferritin ≥ 30 ng/mL during the screening period

    • Subjects who have been receiving ESAs:
  • Subjects with renal anemia who have been receiving ESA within the doses approved in Japan for more than 8 weeks after starting peritoneal dialysis, before the screening assessment
  • Mean of the subject's two most recent Hb values before randomization during the Screening Period must be ≥10.0 g/dL and ≤12.0 g/dL
  • TSAT ≥ 20% or serum ferritin ≥ 100 ng/mL during the screening period

Exclusion criteria

Exclusion Criteria:

  • Subjects who had trouble with continuing peritoneal dialysis due to peritonitis, development of catheter trouble (e.g. tunnel infection) within 4 weeks before the screening assessment
  • Concurrent retinal neovascular lesion requiring treatment and macular edema requiring treatment
  • Concurrent disease with inflammation that could impact erythropoiesis
  • History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastro-paresis
  • Uncontrolled hypertension
  • Concurrent congestive heart failure ( Class III or higher)
  • History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the screening assessment
  • Positive for surface antigen (HBsAg) or anti- virus (HCV) antibody at the screening assessment, or positive for (HIV) in a past test
  • Concurrent other form of anemia than renal anemia
  • Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the screening assessment
  • (AST), Alanine Aminotransferase (ALT), total , or Alkaline Phosphatase (ALP) that is greater than the criteria below, or previous or concurrent another serious liver disease at screening assessment
  • Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
  • Having undergone blood transfusion and/or a surgical procedure considered to promote anemia (excluding shunt reconstruction surgery for access to the blood) within 4 weeks before the screening assessment
  • Having undergone a kidney transplantation
  • Having a previous history of treatment with ASP1517
  • History of serious drug allergy including anaphylactic shock
  • Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before acquisition
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    ASP1517 Low Dose Group (ESA Untreated)

    This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.

    Drug: roxadustat

  • Experimental
    ASP1517 High Dose Group (ESA Untreated)

    This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.

    Drug: roxadustat

  • Experimental
    ASP1517 ESAs Treated Group

    This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.

    Drug: roxadustat

Interventions

06

What researchers measure

Primary outcomes

  1. Hemoglobin (Hb) Response Rate from Week 18 to Week 24

    Hb response defined as average Hb within the target range in this outcome

    Time frame: Up to Week 24

Secondary outcomes

  1. Hb Response rate

    Hb response is defined as reaching target values for Hb and change of Hb from baseline in this outcome.

    Time frame: Up to Week 24

  2. Average Hb levels from week 18 to week 24

    Time frame: Up to week 24

  3. Change from baseline in the average Hb levels of week 18 to week 24

    Time frame: Baseline and up to Week 24

  4. Rate of rise in Hb levels (g/dL/week)

    Time frame: Up to Week 4

  5. Proportion of time points with target Hb levels

    Time frame: Up to Week 24

  6. Proportion of participants who achieve the target Hb level at each week

    Time frame: Up to Week 24

  7. Proportion of participants who achieve the lower limit of the target Hb level

    Time frame: Up to Week 24

  8. Time to achieve the lower limit of the target Hb level

    Time frame: Up to Week 24

  9. Change from baseline in Hb level at each week

    Time frame: Baseline and Up to Week 24

  10. Efficacy assessed by hematocrit

    Hematocrit will be summarized by ASP1517 low dose Erythropoieses Stimulating Agent (ESA) untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  11. Efficacy assessed by reticulocytes/ erythrocytes

    Reticulocytes/Erythrocytes will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  12. Efficacy assessed by Iron (Fe)

    Fe will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  13. Efficacy assessed by ferritin

    Ferritin will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  14. Efficacy assessed by transferrin

    Transferrin will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  15. Efficacy assessed by total iron binding capacity

    Total iron binding capacity will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  16. Efficacy assessed by soluble transferrin receptor

    Soluble transferrin receptor will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  17. Efficacy assessed by transferrin saturation

    Transferrin saturation will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  18. Efficacy assessed by reticulocyte hemoglobin content

    Reticulocyte hemoglobin content will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group.

    Time frame: Up to Week 24

  19. Quality of life assessed by SF-36

    SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey

    Time frame: Up to Week 24

  20. Quality of life assessed by EQ-5D

    EQ-5D: EuroQol 5 Dimension

    Time frame: Up to Week 24

  21. Quality of life assessed by FACT-An

    FACT-An: Functional Assessment of Cancer Therapy-Anemia

    Time frame: Up to Week 24

  22. Occurrence of hospitalizations

    Time frame: Up to Week 24

  23. Safety assessed by incidence of adverse events

    Time frame: Up to Week 24

  24. Number of participants with abnormal Vital signs and/or adverse events related to treatment

    Time frame: Up to Week 24

  25. Safety assessed by standard 12-lead electrocardiogram

    Time frame: Up to Week 24

  26. Number of participants with abnormal Laboratory values and/or adverse events related to treatment

    Time frame: Up to Week 24

  27. Plasma concentration of unchanged ASP1517

    Time frame: Up to Week 24

07

Study locations

15 sites
  • Site JP00002
    Aichi, Japan
  • Site JP00004
    Aichi, Japan
  • Site JP00010
    Aichi, Japan
  • Site JP00013
    Aichi, Japan
  • Site JP00001
    Fukuoka, Japan
  • Site JP00005
    Fukuoka, Japan
  • Site JP00012
    Hokkaido, Japan
  • Site JP00014
    Hokkaido, Japan
  • Site JP00006
    Ishikawa, Japan
  • Site JP00008
    Kanagawa, Japan
  • Site JP00003
    Nagano, Japan
  • SIte JP00015
    Okayama, Japan
  • Site JP00009
    Osaka, Japan
  • Site JP00007
    Tokushima, Japan
  • Site JP00011
    Toyama, Japan
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Aug 2017, 13 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 13 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
May 23, 2016
StartActual
Jun 22, 2016
Primary completionActual
Aug 2, 2017
CompletionActual
Aug 2, 2017
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02780726
Collaborators
FibroGen
Responsible party
Sponsor
First posted
May 23, 2016
Start date
Jun 22, 2016
Primary completion
Aug 2, 2017
Completion
Aug 2, 2017
Last update
Oct 30, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion